Antisense modulation of CD81 expression
AssigneeIsis Pharmaceuticals, Inc.
InventorsMark J. Graham, Kenneth Dobie
Life of this patent
Estimating the term…
Abstract
Antisense compounds, compositions and methods are provided for modulating the expression of CD81. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding CD81. Methods of using these compounds for modulation of CD81 expression and for treatment of diseases associated with expression of CD81 are provided.
Claims20
A compound 8 to 50 nucleobases in length targeted to a nucleic acid molecule encoding CD81, wherein said compound specifically hybridizes with said nucleic acid molecule encoding CD81 and inhibits the expression of CD81.
A compound 8 to 50 nucleobases in length which specifically hybridizes with at least an 8-nucleobase portion of an active site on a nucleic acid molecule encoding CD81.
Dependencies are inferred from the claim text.